Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Voxelotor. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2C8 | P10632 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.34 |
| ▸ | ERN1 | O75460 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.31 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | GCK | P35557 | 1/20 | 0.30 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Voxelotor SCHEMBL16539273 | 0.99 | CYP1A2 (0.98) | CYP1A2CYP3A4CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL23996869 | 0.94 | CYP1A2 (0.88) | CYP1A2CYP3A4CYP2C8CYP2C9CYP2C19 | |
| Voxelotor SCHEMBL21519369 | 0.93 | CYP1A2 (0.87) | CYP1A2CYP3A4CYP2C8CYP2C9CYP2C19 | |
| Voxelotor SCHEMBL21519346 | 0.92 | CYP1A2 (0.85) | CYP1A2CYP3A4CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL17468601 | 0.92 | CYP1A2 (0.85) | CYP1A2CYP3A4CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL16671919 | 0.90 | CYP1A2 (0.82) | CYP1A2CYP3A4CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL17501938 | 0.89 | CYP1A2 (0.80) | CYP1A2CYP3A4CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL16996826 | 0.89 | CYP1A2 (0.80) | CYP1A2CYP3A4CYP2C8CYP2C9CYP2C19 | |
| Voxelotor SCHEMBL18114824 | 0.89 | CYP1A2 (0.79) | CYP1A2CYP3A4CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL15068330 | 0.88 | CYP1A2 (0.79) | CYP1A2CYP3A4CYP2C8CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 752 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107472-A1 | TREATMENT OF SICKLE CELL DISEASE, VASO-OCCLUSIVE CRISES-ASSOCIATED DISEASES, AND/OR THROMBOSIS WITH A HEMOGLOBINASE ENZYME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2026-05-21 | — | — | WO | claimed |
| US-12629363-B2 | Prophylaxis and treatment of angioedema | PHARVARIS GMBH (CH) | 2026-05-19 | — | — | US | claimed |
| US-20260108550-A1 | NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND USE THEREOF IN THE TREATMENT AND PREVENTION OF A RED BLOOD CELL DISORDER | NUVAMID SA (CH) | 2026-04-23 | — | — | US | claimed |
| US-20260098028-A1 | Compounds and Their Use for Treatment of Hemoglobinopathies | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-04-09 | — | — | US | claimed |
| EP-4698636-A2 | PATROLLING MONOCYTE CELLULAR THERAPY | New York Blood Center, Inc. (US) | 2026-02-25 | — | — | EP | claimed |
| EP-4688867-A2 | ANTI-TMPRSS6 ANTIBODIES AND USES THEREOF | Disc Medicine, Inc. (US) | 2026-02-11 | — | — | EP | claimed |
| US-12544403-B2 | Methods to treat mitochondrial-associated dysfunctions or diseases | THE GENERAL HOSPITAL CORPORATION (US) | 2026-02-10 | — | — | US | claimed |
| US-12492180-B2 | Process and intermediates for the preparation of Voxelotor | CURIA SPAIN, S.A.U. (ES) | 2025-12-09 | — | — | US | claimed |
| US-12472164-B2 | Masitinib for the treatment of sickle cell disease | AB SCIENCE (FR) | 2025-11-18 | — | — | US | claimed |
| US-20250297015-A1 | DRUG CONDITIONING REGIMEN FOR SICKLE CELL DISEASE | NEW YORK BLOOD CENTER INC (US) | 2025-09-25 | — | — | US | claimed |
| US-20170174654-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2017-06-22 | — | — | US | claimed |
| WO-2017083281-A1 | METHOD OF AMELIORATING SIDE EFFECTS OF SICKLE CELL DISEASE TREATMENTS | ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. (US) | 2017-05-18 | — | — | WO | claimed |
| US-20160303099-A1 | METHODS OF TREATMENT | GLOBAL BLOOD THERAPEUTICS, INC. | 2016-10-20 | — | — | US | claimed |
| WO-2016160755-A1 | ALDEHYDE COMPOUNDS FOR TREATING PULMONARY FIBROSIS, HYPOXIA, AND CONNECTIVE TISSUE AND AUTOIMMUNE DISEASE | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2016-10-06 | — | — | WO | claimed |
| US-20160206614-A1 | SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | GLOBAL BLOOD THERAPEUTICS, INC. | 2016-07-21 | — | — | US | claimed |
| US-20150344472-A1 | SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | GLOBAL BLOOD THERAPEUTICS, INC. | 2015-12-03 | — | — | US | claimed |
| US-9018210-B2 | Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2015-04-28 | — | — | US | claimed |
| EP-2797416-A1 | SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | Global Blood Therapeutics, Inc. (US) | 2014-11-05 | — | — | EP | claimed |
| US-20130190315-A1 | SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2013-07-25 | — | — | US | claimed |
| WO-2013102142-A1 | SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2013-07-04 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174654-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | CYP1A2 760/4885CYP3A4 341/4885CYP2C8 396/4885 |
| US-20260108550-A1 | NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND USE THEREOF IN THE TREATMENT AND PREVENTION OF A RED BLOOD CELL DISORDER | HBG1, KYNU, NNT | CYP1A2 2071/4885CYP3A4 1888/4885CYP2C8 1158/4885 |
| US-20150344472-A1 | SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | HBB, HBG2, MB | CYP1A2 447/4885CYP3A4 201/4885CYP2C8 129/4885 |
| US-12472164-B2 | Masitinib for the treatment of sickle cell disease | MPST, KSR2, HCLS1 | CYP1A2 2780/4885CYP3A4 3353/4885CYP2C8 2306/4885 |
| US-20160206614-A1 | SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | HBB, HBG2, MB | CYP1A2 447/4885CYP3A4 201/4885CYP2C8 129/4885 |
| US-20130190315-A1 | SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | HBB, HBG2, MB | CYP1A2 447/4885CYP3A4 201/4885CYP2C8 129/4885 |
| US-20260098028-A1 | Compounds and Their Use for Treatment of Hemoglobinopathies | HBZ, HBG2, HBB | CYP1A2 604/4885CYP3A4 322/4885CYP2C8 1044/4885 |
| US-12544403-B2 | Methods to treat mitochondrial-associated dysfunctions or diseases | TFAM, FH, HSPA9 | CYP1A2 1444/4885CYP3A4 3637/4885CYP2C8 2777/4885 |
| US-20160303099-A1 | METHODS OF TREATMENT | HIF1AN, HIF1A, SSB | CYP1A2 2550/4885CYP3A4 4418/4885CYP2C8 2835/4885 |
| US-12492180-B2 | Process and intermediates for the preparation of Voxelotor | VPS51, KIF15, VAT1 | CYP1A2 1436/4885CYP3A4 1138/4885CYP2C8 3404/4885 |
| US-12629363-B2 | Prophylaxis and treatment of angioedema | BDKRB2, BDKRB1, HRH2 | CYP1A2 947/4885CYP3A4 1498/4885CYP2C8 1124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.